Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Cloudiness develops when peptides are mixed improperly (shaken instead of swirled), reconstituted at temperatures above 25C, or when bacterial growth occurs in preservative-free solutions
Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations
Do I need a prescription to use LIPO-C for a B12 protocol
Low-density lipoprotein transports cholesterol through the bloodstream
